Tag: Novartis

Novartis says No to Novarish

In a landmark decision, the Bombay High Court granted Novartis AG an ad-interim injunction against Novarish Healthcare Private Limited for trademark infringement. Novartis successfully argued that Novarish’s use of the “NOVARISH” mark was deceptively similar to its well-known “NOVARTIS” trademark, leading to the court’s decision to protect Novartis’s intellectual property rights.

Read more about Novartis says No to Novarish

Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).

Read more about Cancerous Battle: Novartis and NATCO clash over Eltrombopag

Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents

Learn about the patent cliff and how Novartis’ heart failure drug Vymada (Entresto®) will expire its patent protection in 2023. Find out more about secondary patents that can extend market exclusivity of Entresto® until 2033.

Read more about Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents

In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies

During the last two days, two interesting articles addressing accessibility of medical products and methods were published. While one article in 'The Hindu' spoke about...

Read more about In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies